NDAORALSOLUTION1 Generic Approved
Approved
Feb 2016
Lifecycle
Post-LOE
Competitive Pressure
50/100
Clinical Trials
20
Data completeness
5/8 — Partial
BRIVIACT (brivaracetam) by UCB Pharma is epoxide hydrolase inhibitors [moa]. First approved in 2016.
Drug data last refreshed 3h ago · AI intelligence enriched 5d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Briviact (brivaracetam) is a small-molecule oral antiepileptic drug approved in 2016 that works as an epoxide hydrolase inhibitor to reduce seizure frequency. It is indicated for adjunctive treatment of partial-onset seizures in patients with epilepsy. The drug represents a novel mechanism within the antiepileptic space, targeting a distinct pathway from traditional anticonvulsants.
Post-LOEPost-LOE
Product is in post-LOE phase with 50% competitive pressure, indicating a mature, stable brand team focused on defense and market maintenance rather than expansion.
Mechanism of Action
Epoxide Hydrolase Inhibitors
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
Started Jul 2024
70 enrolled
Childhood Absence EpilepsyJuvenile Absence Epilepsy
A Study to Assess the Bioequivalence Between Brivaracetam Tablet and Dry Syrup in Healthy Japanese Male Study Participants
Started Mar 2024
64 enrolled
Healthy Study Participants
A Study to Assess the Bioequivalence Between Brivaracetam Tablet and Dry Syrup in Healthy Male Japanese Study Participants
Started Apr 2022
24 enrolled
Healthy Study Participants
A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
Started Mar 2022
84 enrolled
Childhood Absence EpilepsyJuvenile Absence Epilepsy
A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
Started Jul 2021
153 enrolled
Childhood Absence EpilepsyJuvenile Absence Epilepsy
Worked on BRIVIACT at UCB Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.